Comments on the Fourth International Conference on Bispecific Antibodies and Cellular Cytotoxicity, Duck Key, Florida, March 1-5, 1995.
Fanger
M W
MW
Ball
E D
ED
Drakeman
D L
DL
D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity; D002986:Clinical Trials as Topic; D004337:Drug Carriers; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D007239:Infections / Q000628:therapy; D008213:Lymphocyte Activation; D051379:Mice; D008822:Mice, Transgenic; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage
D018033:Antibodies, Bispecific; D004337:Drug Carriers; D018796:Immunoconjugates; D014612:Vaccines